Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 4/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17548036 | 0.95 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27049743 | 0.94 | MAOB (0.37) | SLC6A2SLC6A4SLC6A3MAOBMAOA | |
| SCHEMBL9764129 | 0.88 | NOS3 (0.33) | SLC6A2SLC6A4SLC6A3MAOBMAOA | |
| SCHEMBL9764135 | 0.88 | NOS3 (0.33) | SLC6A2SLC6A4SLC6A3MAOBMAOA | |
| SCHEMBL9763568 | 0.86 | NOS3 (0.32) | SLC6A2SLC6A4SLC6A3MAOBMAOA | |
| SCHEMBL9763573 | 0.86 | NOS3 (0.32) | SLC6A2SLC6A4SLC6A3MAOBMAOA | |
| SCHEMBL9763571 | 0.86 | NOS3 (0.32) | SLC6A2SLC6A4SLC6A3MAOBMAOA | |
| SCHEMBL12895669 | 0.83 | NOS3 (0.31) | SLC6A2SLC6A4SLC6A3MAOBMAOA | |
| SCHEMBL18503351 | 0.83 | NOS3 (0.31) | SLC6A2SLC6A4SLC6A3MAOBMAOA | |
| SCHEMBL17548067 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170029698-A1 | ANTIOXIDANT FOR LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE USING LIQUID CRYSTAL COMPOSITION | DIC CORPORATION (JP) | 2017-02-02 | — | — | US | disclosed |
| US-9487704-B2 | Nematic liquid crystal composition and liquid crystal display element using same | DIC CORPORATION (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160319195-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT USING THE SAME | DIC CORPORATION (JP) | 2016-11-03 | — | — | US | disclosed |
| US-20160060526-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAME | DIC CORPORATION (JP) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029698-A1 | ANTIOXIDANT FOR LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE USING LIQUID CRYSTAL COMPOSITION | GPX1, LPO, SCO2 | SLC6A2 2770/4885SLC6A4 4137/4885SLC6A3 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.